Repairing mandibular defect by gene-modified bone marrow mesenchymal stem cells combined with coral hydroxyapatite scaffold in osteoporotic rats
You-chao Tang,Yuan-qin Wang,Wei Tang
DOI: https://doi.org/10.3321/j.issn:1673-8225.2008.14.002
2008-01-01
Abstract:Background: In recent years, tissue engineered bone by gene-modified stem cells compounded with scaffold materials in repair of bone defect has provided a novel thought for the bone tissue reconstruction. Objective: To explore the effect on repairing mandibular defect with human bone morphogenetic protein-2 (hBMP-2) gene transfected bone marrow mesenchymal stem cells (BMSCs) compounded with coral hydroxyapatite (CHA) scaffolds in osteoporotic rats. Design, time and setting: A randomized control animal experiment was completed at the Key Laboratory for Oral Biomedical Engineering by the State Ministry of Education from June 2005 to October 2006. Materials: Twenty-four unpregnant female Sprague-Dawley rats, 6 months old, SPF gradem weighing 250-300 g, were used to establish models of postmenopausal osteoporosis, The pcDNA3.1-hBMP-2 recombinant plasmid carrying hBMP-2 was offered by the Third Military Medical University of Chinese PLA; CHA scaffolds was offered by the Key Laboratory for Oral Biomedical Engineering by the State Ministry of Education. Methods: Twenty-four SD rats were divided into experimental group and control group at random, each containing 12 animals. Three months later, BMSCs harvested from osteoporotic rats were transfected by pcDNA3.1-hBMP-2 recombinant plasmid, and control group leaved untreated. Three days later, the transfected and untransfected autogenous BMSCs were seeded into CHA scaffolds, respectively. Then the cell/scaffolds composites were implanted into the critical-size defect area in the mandible bone of osteoporotic rats. Main outcome measures: At the 4th and 8th weeks after implantation, immunohistochemical analysis was performed to evaluate the new bone formation, and the amount of newly formed bone was detected semi-quantitatively at the 8th weeks. Results: All 24 SD rats were involved in the result analysis. 1 Newly formed bone was found at the margin of the defect area treated with the BMSCs modified by BMP-2 gene transfer at 4 weeks after implantation. The lamellar bone matrix was visible at 8 weeks. In the control group, only a little bone matrix was observed at the margin of CHA material at 4 weeks after implantation, however, the amount of newly formed bone was much less than the experimental group, and there was some adipose-like tissues at defect margins and central part at 8 weeks after implantation. 2 The percentage of newly formed bone area was (0.046±0.004)% and (0.233±0.015)% in the control group and the experimental group, respectively. There were significant differences in the amount of newly formed bone between two groups (P < 0.01). Conclusion: Tissue engineered bone formed by hBMP-2 gene-modified BMSCs in conjunction with CHA scaffolds, can allow large bone formation for treatment of mandibular defect in osteoporosis rats.